Palvella Therapeutics
PVLA
60 hedge funds and large institutions have $33.4M invested in Palvella Therapeutics in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 20 reducing their positions, and 9 closing their positions.
435% more call options, than puts
Call options by funds: $107K | Put options by funds: $20K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.02% less ownership
Funds ownership: 0.59% → 0.58% (-0.02%)
5% less funds holding
Funds holding: 63 → 60 (-3)
9% less capital invested
Capital invested by funds: $36.7M → $33.4M (-$3.3M)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
40% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$4.54M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$2.08M |
| 3 |
Walleye Capital
New York
|
+$693K |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$444K |
| 5 |
OCA
Octagon Capital Advisors
New York
|
+$436K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$5.27M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$854K |
| 3 |
Millennium Management
New York
|
-$688K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$501K |
| 5 |
Renaissance Technologies
New York
|
-$437K |
PVLA Hedge Fund Activity: Q1 2023 in Review
60 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q1 2023, worth a combined $33.4M — down 9% from $36.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PVLA and 6 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 12 added.
The largest buyer was Soleus Capital Management, adding an estimated $4.54M. The largest seller was Bank of America, cutting an estimated $5.27M.
- 60 institutional investors held Palvella Therapeutics (PVLA) as of Q1 2023, down from 63 in Q4 2022.
- Funds reported $33.4M of Palvella Therapeutics stock for Q1 2023, down 9% quarter-over-quarter.
- 6 funds opened new Palvella Therapeutics positions in Q1 2023 and 9 closed out, a net change of -3 holders.
- The largest Palvella Therapeutics buyer in Q1 2023 was Soleus Capital Management, an estimated $4.54M added.
- The largest Palvella Therapeutics seller in Q1 2023 was Bank of America, an estimated $5.27M sold.
Based on aggregated 13F filings for Q1 2023.